Summary

Eligibility
for people ages 18-60 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Official Title

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

Keywords

Proteinuric Kidney Disease, Kidney Diseases, VX-147

Eligibility

You can join if…

Open to people ages 18-60

You CAN'T join if...

Other protocol defined Inclusion/Exclusion criteria apply.

Locations

  • UCSF School of Medicine accepting new patients
    San Francisco California 94143 United States
  • The Medical Research Group, Inc accepting new patients
    Fresno California 93720 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
ID
NCT05312879
Phase
Phase 2/3 Kidney Disease Research Study
Study Type
Interventional
Participants
Expecting 466 study participants
Last Updated